Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Lung Neoplasms 12Multiple Myeloma 11Lymphoma 10Neoplasm Metastasis 9Melanoma 7Leukemia, Myeloid, Acute 7Prostatic Neoplasms 6Neuroblastoma 6Carcinoma, Non-Small-Cell Lung 6Wilms Tumor 5Medulloblastoma 5Lymphoma, Non-Hodgkin 5Fallopian Tube Neoplasms 5Burkitt Lymphoma 5Breast Neoplasms 5Triple Negative Breast Neoplasms 4Small Cell Lung Carcinoma 4Rhabdoid Tumor 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Pancreatic Neoplasms 4Ovarian Neoplasms 4Osteosarcoma 4Neuroectodermal Tumors, Primitive, Peripheral 4Histiocytosis, Langerhans-Cell 4Hepatoblastoma 4Glioma 4Ependymoma 4Central Nervous System Neoplasms 4Sarcoma, Kaposi 3Sarcoma 3

Interventions

trastuzumab biosimilar HLX02 1exemestane 1X-Rays 1Trastuzumab 1Taxes 1TVB-2640 1Specimen Handling 1Paclitaxel 1PF-05280014 1Ontruzant 1Ogivri 1Magnetic Resonance Spectroscopy 1Letrozole 1Fulvestrant 1Disulfides 1CT-P6 1Biopsy 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Advanced Breast Carcinoma × Specimen Handling × Clear all
NCT03179904 2026-05-05

TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer

Mayo Clinic

Phase 2 Active not recruiting
17 enrolled 10 charts
Breast

Advanced Breast Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡